Alphatec DIGITAL

Target: Alphatec Holdings, Inc. (NASDAQ: ATEC)

Research date: 26 October 2026

Scope: Enterprise technology, digital medical platforms, clinical data infrastructure, Israeli technology relationships, state-sector provision, relevant corporate subsidiaries and controlling principals.

Enterprise Technology Stack & Vendor Relationships

Corporate technology operations

Alphatec Holdings, Inc. is a US medical technology company headquartered in Carlsbad, California, whose business includes developing surgical technologies for spinal disorders. Its operating group includes Alphatec Spine, SafeOp Surgical and EOS imaging.¹

The company’s reported technology portfolio includes the AlphaInformatiX/InformatiX ecosystem, integrating medical imaging, intraoperative neuromonitoring, AI-assisted surgical planning and clinical information platforms.²

EOS imaging acquisition and integration

Alphatec announced a proposed acquisition of EOS imaging on 28 February 2020, describing the French company’s capabilities in low-dose orthopaedic imaging, three-dimensional modelling and surgical planning software.³

Alphatec terminated that original acquisition agreement in April 2020 following its assessment of the effects of the COVID-19 pandemic.⁴

On 16 December 2020, Alphatec announced a revised acquisition agreement valuing EOS equity at approximately $79.7 million, with approximately $37.2 million of debt retirement.⁵

The May 2021 tender-offer announcement established that Alphatec would hold approximately 89% of EOS common shares and voting rights following settlement.⁶

On 7 June 2021, Alphatec announced the completion of the combination and described the integration of EOS imaging into its surgical information ecosystem.⁷

EOS imaging currently identifies itself as part of the ATEC Spine Group and describes medical imaging, three-dimensional anatomical modelling, surgical planning and postoperative assessment as its principal technology applications.⁸

SafeOp Surgical

On 8 March 2018, Alphatec announced the acquisition of SafeOp Surgical, a developer of automated neuromonitoring systems designed to assess neurological function during spinal surgery. [pre-2020; continuing ownership confirmed through later corporate disclosures].⁹

Alphatec’s 2019 regulatory announcement described SafeOp’s automated electromyography (EMG) and somatosensory evoked potential (SSEP) technologies, including rapid intraoperative neurological signal processing. [pre-2020; technology subsequently integrated into the Alphatec product portfolio].¹⁰

Named enterprise and clinical systems

Alphatec’s July 2024 launch announcement describes EOS Insight as a cloud-based software platform combining EOSedge imaging, AI-assisted measurements, three-dimensional surgical planning, patient-specific implant planning and postoperative analytics.¹¹

The current EOS product information describes browser and mobile access to patient-specific clinical information, including alignment measurements and surgical planning data.¹²

The January 2026 Alphatec investor presentation identifies EOS Insight and the Valence platform within the company’s evolving surgical technology ecosystem.¹³

Israeli-origin enterprise software procurement

No public evidence identified establishing that Alphatec currently licenses, subscribes to or integrates Check Point, Wiz, SentinelOne, CyberArk, Nice, Verint, Claroty, Palo Alto Networks or comparable Israeli-origin cybersecurity software.

Systems integrators and IT outsourcing

No public evidence identified of a named systems integrator or IT outsourcing partner deploying Israeli-origin enterprise software within Alphatec’s infrastructure.

Scale of Israeli-origin technology dependency

No public evidence identified establishing a material dependency on Israeli-origin enterprise cybersecurity, communications, analytics or cloud technology.

Surveillance, Biometrics & Retail Technology

Clinical monitoring technology

Alphatec’s SafeOp system uses automated EMG and SSEP signal processing to assist surgeons in monitoring nerve location and neurological function during spinal procedures. The company described its clinical applications and FDA clearance in its January 2019 announcement. [pre-2020; continuing product-line integration confirmed].¹⁰

Patient-specific imaging and analytics

Alphatec’s July 2024 announcement identifies the processing of clinical imaging measurements, patient-specific spinal geometry, surgical planning information and postoperative patient analytics through EOS Insight.¹¹

Alphatec’s current EOS documentation describes AI-based alignment measurement, clinical image interpretation, patient-specific planning and surgical outcome assessment.¹²

The company describes the applications as clinical assessment and spinal surgery support; the cited documentation does not identify retail surveillance, facial recognition or civilian identity verification as product functions.¹²

Israeli-origin facial recognition and biometrics

No public evidence identified of Alphatec deploying facial recognition, gait identification, biometric identification or behavioural surveillance products supplied by Trigo, BriefCam, AnyVision/Oosto, Trax or comparable Israeli-origin vendors.

Predictive policing and workforce surveillance

No public evidence identified of Alphatec using Israeli-origin predictive policing, sentiment analysis, social media monitoring or workforce surveillance systems.

Indirect third-party deployment

No public evidence identified establishing that Israeli-origin surveillance or biometric technologies reach Alphatec through managed security providers, platform integrations or bundled enterprise software.

Cloud Infrastructure, Data Residency & Sovereign Cloud Participation

Cloud-based clinical software

On 24 July 2024, Alphatec announced EOS Insight as a cloud-based platform incorporating a user portal, AI-assisted clinical assessment and applications covering preoperative, intraoperative and postoperative care.¹¹

The company’s announcement specifically identifies cloud connectivity enabling the export of clinical data for comparisons between preoperative plans, intraoperative measurements and postoperative assessments.¹¹

Alphatec’s current product documentation describes desktop and mobile access to EOS Insight, including patient-specific imaging measurements and surgical plans.¹²

Clinical data processing

EOS imaging describes a global installed base of approximately 500 systems across 40 countries, supporting more than one million patient examinations annually. These figures describe the imaging ecosystem and do not establish that all examinations are transferred to Alphatec’s cloud services.⁸

The EOS Insight product description establishes that the platform processes patient-specific measurements and provides associated clinical analysis; the available description does not identify the location of hosting infrastructure, backup facilities, model-training infrastructure or the relevant cloud processor.¹²

Historical Israeli clinical customer

On 6 April 2017, HealthManagement published an EOS imaging announcement identifying Tel Aviv Sourasky Medical Center as the first purchaser of an EOS imaging system in Israel, with installation expected at Dana-Dwek Hospital during April 2017. [pre-2020; subsequent installation, current operation and continuing service status unknown].¹⁴

The transaction preceded Alphatec’s 2021 acquisition of EOS imaging and therefore establishes a historical customer relationship of a subsequently acquired business, rather than a transaction originally undertaken by Alphatec Holdings.^{6, 14}

The 2017 report concerned the sale of medical imaging equipment and did not identify a cloud-hosting contract, patient-data processing location or government digital infrastructure project.¹⁴

Israeli data residency and jurisdiction

No public evidence identified establishing that Alphatec or EOS Insight stores, processes, routes or replicates clinical data through Israeli-hosted infrastructure.

No public evidence identified establishing that Israeli authorities have contractual or operational access to Alphatec’s global cloud infrastructure.

The available sources do not establish whether historical EOS imaging customers in Israel currently transmit patient data to Alphatec-controlled cloud systems.

Israeli data centres

No public evidence identified of Alphatec operating, leasing or colocating data-centre facilities in Israel.

Project Nimbus and government cloud programmes

No public evidence identified of Alphatec participation in Project Nimbus or another Israeli government cloud-infrastructure initiative.

Sovereign cloud and infrastructure resilience

No public evidence identified of Alphatec providing sovereign-cloud, government data-residency or infrastructure-resilience services to Israeli state or military institutions.

Defence, Intelligence & Security Sector Technology Relationships

Military and intelligence procurement

No public evidence identified of contracts between Alphatec Holdings or its identified subsidiaries and the Israeli Ministry of Defence, Israel Defence Forces, Israeli intelligence agencies or other Israeli national-security institutions.

Historical medical technology activity in Israel

EOS imaging announced the sale of a clinical imaging system to Tel Aviv Sourasky Medical Center in 2017. The announcement identifies a civilian hospital customer and an orthopaedic imaging application. [pre-2020; subsequent servicing status unknown].¹⁴

No public evidence identified linking that hospital transaction to an Israeli military or intelligence procurement programme.

Military-related governance backgrounds

Alphatec’s current board disclosures identify David Pelizzon as a retired United States Army officer who served in airborne and special operations units and who is associated with Squadron Capital.¹⁵

The same disclosures identify Dave Demski as a former executive of Globus Medical who previously held a position with Gilo Ventures.¹⁵

No public evidence identified establishing that either background resulted in Alphatec supplying technology to Israeli defence or intelligence organisations.

Dual-use medical technology

Alphatec’s SafeOp platform provides automated neurological monitoring for surgery, while EOS Insight supports clinical imaging, patient-specific planning and surgical assessment.^{10, 11}

No public evidence identified of these products being deployed by Israeli military or intelligence bodies for surveillance, intelligence collection or security operations.

Offensive cyber and digital weapons

No public evidence identified of Alphatec developing, licensing, selling or maintaining offensive cyber capabilities, zero-day exploitation systems, military cyber tools or digital weapons for Israeli state actors.

Settlement-specific digital provision

No public evidence identified of Alphatec providing software, cloud services, surveillance tools or digital infrastructure specifically to Israeli settlements in the occupied Palestinian territories or occupied Syrian Golan.

Provision after international legal developments

No public evidence identified establishing continued Israeli military, intelligence or settlement-related technology provision by Alphatec after 19 July 2024 or after November 2024.

The historical 2017 EOS imaging sale cannot independently establish such continuing provision.¹⁴

AI, Algorithmic & Autonomous Systems

Clinical AI applications

Alphatec launched EOS Insight commercially on 24 July 2024, describing its integration of AI-assisted alignment calculations with medical imaging and three-dimensional surgical planning.¹¹

The launch announcement identifies OrthoIndy Hospital in the United States as the location of the first customer implementation, where surgeons David Schwartz and Craig McMains performed the initial announced EOS Insight-informed procedures.¹¹

Independent reporting by Becker’s Spine Review on 24 July 2024 corroborated the product launch and its application in clinical spinal surgery.¹⁶

AI-driven surgical planning

The EOS Insight platform processes EOSedge imaging to generate anatomical alignment measurements, patient-specific spinal models, surgical planning simulations and postoperative comparison data.¹²

The July 2024 announcement also describes the generation of patient-specific rod contours and the integration of imaging information into clinical planning and intraoperative assessment.¹¹

Technology development and commercial continuity

In September 2026, Alphatec appointed Thomas “Tommy” Carls as Executive Vice President, Data Intelligence and Strategy, assigning him responsibility for EOSedge, EOS Insight, data acquisition and analytics and the wider InformatiX strategy.¹⁷

Alphatec’s 2026 investor presentation reported the launch of EOS Insight in Australia/New Zealand during Q4 2025, establishing continued international commercial expansion of the clinical software platform.¹³

AI model development and datasets

Alphatec’s product description establishes the use of AI-assisted clinical measurements and patient-specific image analysis but does not identify the precise geographical origin of model-training datasets.¹²

No public evidence identified establishing that Alphatec models were trained on Israeli military datasets, intercepted communications or surveillance-derived information from occupied territories.

Israeli government AI procurement

No public evidence identified of Alphatec providing AI or machine-learning platforms to Israeli state, military, intelligence or security institutions.

Israeli healthcare AI deployment

No public evidence identified establishing deployment of EOS Insight’s cloud-based AI functionality to the historical Israeli EOS imaging customer or another identified Israeli healthcare institution.

Autonomous military systems

No public evidence identified of Alphatec providing autonomous target generation, military threat detection, automated human targeting or military surveillance-tracking systems to Israeli security institutions.

Purpose-built targeting and weapons systems

No public evidence identified of Alphatec developing software whose primary designed output is kinetic military targeting, fire-control decisions, kill-chain automation or weapons effects.

Technology Ecosystem & R&D Footprint

Research and development structure

Alphatec’s January 2026 investor presentation describes continuing investment in clinical informatics, surgical technology and international market development, including EOS Insight and its wider surgical ecosystem.¹³

The September 2026 appointment of Tommy Carls to a dedicated data intelligence and strategy position further identifies the company’s continuing organisational investment in clinical data acquisition, analytics and software development.¹⁷

Acquisition of SafeOp

Alphatec acquired SafeOp Surgical in March 2018, adding automated intraoperative neuromonitoring capabilities to its technology portfolio. [pre-2020; continuing integration confirmed through subsequent disclosures].⁹

Acquisition of EOS imaging

Alphatec’s 2020 acquisition announcements identified EOS imaging as a French medical imaging and surgical software company with an international installed base.^{3, 5}

The May 2021 tender-offer announcement and subsequent June 2021 integration announcement establish the transfer of EOS imaging into the Alphatec group.^{6, 7}

International operating footprint

EOS imaging’s corporate description identifies operations in France, the United States, Canada, Germany and Singapore.⁸

Alphatec’s January 2026 investor presentation separately identifies direct-sales operations and associated facilities in Australia/New Zealand and Japan.¹³

Historical Israeli market presence

EOS imaging announced its first Israeli equipment sale in April 2017, identifying Tel Aviv Sourasky Medical Center as the customer. [pre-2020; current commercial relationship unknown].¹⁴

No public evidence identified establishing a dedicated Israeli R&D facility, engineering office, accelerator, innovation laboratory or corporate subsidiary operated by Alphatec.

Corporate principals and investment vehicles

Alphatec identifies Patrick Miles as Chairman and Chief Executive Officer and Mortimer Berkowitz III as lead director, with Berkowitz associated with InnovaHealth Partners and HealthpointCapital.¹⁵

InnovaHealth Partners separately states that its predecessor initially invested in Alphatec in 2005 and that its partners led a significant equity financing in 2017. [pre-2020; the portfolio relationship remains publicly described].¹⁸

Alphatec’s board disclosures also identify directors with backgrounds in medical technology, private investment and corporate finance, including Quentin Blackford, Dave Demski, Karen McGinnis, David Pelizzon and Keith Valentine.¹⁵

No public evidence identified establishing qualifying personal investments or board positions by Alphatec’s controlling principals in NSO Group, Cellebrite, Carbyne, Oosto/AnyVision, Wiz, Check Point, SentinelOne, Verint, Nice or comparable Israeli intelligence and defence technology businesses.

Israeli technology acquisitions and venture investments

No public evidence identified of Alphatec acquiring an Israeli-domiciled technology company or investing directly in an Israeli cybersecurity, surveillance, intelligence or military technology venture.

Patents and academic partnerships

No public evidence identified of a material Alphatec patent co-development arrangement, technology licensing agreement or formal R&D partnership with Technion, Hebrew University, the Weizmann Institute or another Israeli research institution.

Civil Society Scrutiny & Regulatory History

Corporate disclosures

Alphatec’s 2024 Form 10-K provides the company’s regulatory and financial disclosures for the year ended 31 December 2024, including the operations of its medical technology group.¹

The company’s September 2026 announcement identifies continued development of its clinical data and analytics ecosystem through the appointment of a senior executive responsible for data intelligence and strategy.¹⁷

Independent examination of digital clinical systems

Becker’s Spine Review reported Alphatec’s EOS Insight launch in July 2024, identifying the cloud-based software and AI-enabled clinical applications and the initial OrthoIndy implementation.¹⁶

The cited independent reporting concerns medical technology commercialisation and does not document Israeli security-sector use.¹⁶

Historical Israeli commercial activity

The 6 April 2017 HealthManagement publication reproduces an EOS imaging announcement describing its first Israeli medical imaging system sale, naming Tel Aviv Sourasky Medical Center. The announcement preceded Alphatec’s acquisition of EOS imaging. [pre-2020; current contractual status unknown].^{14, 6}

UN and civil-society investigations

No public evidence identified of Alphatec Holdings, Alphatec Spine, SafeOp Surgical or EOS imaging being specifically identified for relevant technology provision in the searched UN OHCHR settlement-database materials, A/HRC/59/23-related searches, Who Profits records or AFSC Investigate searches.

No public evidence identified of a company-specific technology finding concerning Alphatec in the searched material associated with Amnesty International, Human Rights Watch, B’Tselem, Al-Haq, SOMO or Don’t Buy Into Occupation.

Boycott and divestment campaigns

No public evidence identified of an organised boycott or divestment campaign specifically targeting Alphatec for technology provision to Israeli state institutions, the Israeli military or settlements.

No company response to such a campaign was identified.

Regulatory inquiries and legal proceedings

No public evidence identified of Israeli export-control enforcement, sanctions proceedings or regulatory investigations specifically concerning Alphatec’s technology supply to Israeli military, intelligence or settlement-related institutions.

Post-2024 notice and commercial continuity

Alphatec’s January 2026 investor presentation documents international clinical technology expansion, including EOS Insight’s Australia/New Zealand launch in Q4 2025.¹³

The available evidence does not establish that the historical Israeli EOS imaging customer relationship remained active after 19 July 2024 or after November 2024.¹⁴

No public evidence identified of an Alphatec statement addressing the ICJ advisory opinion of 19 July 2024 or the ICC arrest warrants issued in November 2024 in connection with its technology activities.